Matches in Wikidata for { <http://www.wikidata.org/entity/Q89780065> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- Q89780065 description "article scientifique publié en 2020" @default.
- Q89780065 description "artículu científicu espublizáu en febreru de 2020" @default.
- Q89780065 description "im Februar 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q89780065 description "scientific article published on 16 February 2020" @default.
- Q89780065 description "wetenschappelijk artikel" @default.
- Q89780065 description "наукова стаття, опублікована 16 лютого 2020" @default.
- Q89780065 name "Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate-to-severe atopic dermatitis in clinical practice: A retrospective cohort study" @default.
- Q89780065 name "Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate-to-severe atopic dermatitis in clinical practice: A retrospective cohort study" @default.
- Q89780065 type Item @default.
- Q89780065 label "Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate-to-severe atopic dermatitis in clinical practice: A retrospective cohort study" @default.
- Q89780065 label "Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate-to-severe atopic dermatitis in clinical practice: A retrospective cohort study" @default.
- Q89780065 prefLabel "Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate-to-severe atopic dermatitis in clinical practice: A retrospective cohort study" @default.
- Q89780065 prefLabel "Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate-to-severe atopic dermatitis in clinical practice: A retrospective cohort study" @default.
- Q89780065 P1433 Q89780065-656DF29E-54DD-4491-8CDF-C18A59952C7A @default.
- Q89780065 P1476 Q89780065-CB2C28D6-4513-46CC-84BD-6172970B4225 @default.
- Q89780065 P2093 Q89780065-15714D65-4A05-4002-8927-B98A931BDFF1 @default.
- Q89780065 P2093 Q89780065-3689E3FC-B341-43D5-902B-DEAA51D87F7F @default.
- Q89780065 P2093 Q89780065-626E690A-D88B-48EC-B440-B3AE1020C4A4 @default.
- Q89780065 P2093 Q89780065-62CF85C4-E040-40A3-B061-C92167E23E5B @default.
- Q89780065 P2093 Q89780065-8B20AF83-9824-4860-BAE0-0012050221F1 @default.
- Q89780065 P2093 Q89780065-A78DE835-20E5-490B-843E-45A71A735B8E @default.
- Q89780065 P2093 Q89780065-F838F446-F01F-4FD2-89F8-6E28CECB94D7 @default.
- Q89780065 P31 Q89780065-EDEEEDEA-0F12-4709-B0B1-93A62FFFAD24 @default.
- Q89780065 P356 Q89780065-2D2E6F67-454A-4456-9067-77D7CF93DBB0 @default.
- Q89780065 P50 Q89780065-16A844CD-FB2B-47D0-9FCC-FC4426090AAE @default.
- Q89780065 P577 Q89780065-317B0247-D8F8-4571-AB17-1455509057B8 @default.
- Q89780065 P698 Q89780065-54CDAF92-A653-4F1C-865D-8098B5517A81 @default.
- Q89780065 P921 Q89780065-8790F80B-C527-4BA2-B86B-722CC463BD92 @default.
- Q89780065 P356 J.JAAD.2020.02.029 @default.
- Q89780065 P698 32074486 @default.
- Q89780065 P1433 Q15757046 @default.
- Q89780065 P1476 "Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate-to-severe atopic dermatitis in clinical practice: A retrospective cohort study" @default.
- Q89780065 P2093 "Aaron M Drucker" @default.
- Q89780065 P2093 "Arvin Ighani" @default.
- Q89780065 P2093 "Asfandyar Mufti" @default.
- Q89780065 P2093 "Christine E Jo" @default.
- Q89780065 P2093 "Jorge R Georgakopoulos" @default.
- Q89780065 P2093 "Matthew Ladda" @default.
- Q89780065 P2093 "Vincent Piguet" @default.
- Q89780065 P31 Q13442814 @default.
- Q89780065 P356 "10.1016/J.JAAD.2020.02.029" @default.
- Q89780065 P50 Q120401131 @default.
- Q89780065 P577 "2020-02-16T00:00:00Z" @default.
- Q89780065 P698 "32074486" @default.
- Q89780065 P921 Q268667 @default.